Marketing analysis of the drugs used for the treatment of affected military men with brain injuries
DOI:
https://doi.org/10.24959/nphj.14.1940Keywords:
marketing analysis, brain injury, drug therapy, medicinesAbstract
During the research the comparative analysis of protocols of medical care for patients with brain injuries and information of scientific literature and evidence-based medicine has been conducted. It has demonstrated that for the treatment of affected military men with brain injury the following groups of drugs are used: antibacterial agents for systemic use, psychoanaleptics, blood substitutes and perfusion solutions, antiepileptics, vitamins, peripheral vasodilators, cardiac drugs, calcium channel blockers, analgesics, antihemorrhagic drugs, drugs for treating wounds and ulcers, diuretics, antithrombotic agents, antiparkinsonian drugs, psycholeptics, vasoprotectives, beta adrenoreceptor antagonists, etc. Marketing analysis of certain groups of drugs has been conducted according to the following criteria: legal (registration in Ukraine), economic (commercial: country, company), pharmaceutical (types of dosage forms, the composition of active substances, method of application), pharmacotherapeutic (ATC-classification). The analysis of the domestic pharmaceutical market has shown that drugs for treatment of head injuries comprise 1034 drugs manufactured in 39 countries. It has been found that the Ukrainian producers are able to provide the necessary level of rendering medical care in treatment of the traumatic brain injury, they produce 549 names of drugs, and it is almost 53% of the total range of medicines. The first place among the Ukrainian companies manufacturing drugs for treatment of the brain injury has “Darnitsa pharmaceutical company” JSC, the second one – “Yuriа-Farm” Ltd., the third place – Pharmaceutical company “Zdorovye” Ltd. Foreign producers supply 485 drugs (47%). The leaders are India, Germany and Slovenia, which take the first, second and third places in the import of drugs, respectively.
References
База стандартів медичної допомоги в Україні. [Електронний ресурс]. – Режим доступу: http://www. moz.gov.ua/ua/portal/register_standardsof medicalaid.
Белозерцев Ю.А., Запольская Ю.А., Белозерцев Ф.Ю., Юнцев С.В. // Эксперим. и клин. фармакол. – 2012. – №12. – С. 11-14.
Бриф-анализ фармрынка: итоги августа 2013 г. [Электронный ресурс]. – Режим доступа: http://www.apteka.ua/article/251331.
Государственный реестр лекарственных средств Украины [Электронный ресурс]. – Режим доступа: http://www.drlz.kiev.ua.
Дремова Н.Б. // Курский науч.-практ. вестник «Человек и его здоровье». – 2005. – №1. – С. 62-76.
Лихтерман Л.Б. Нейротравматология. – Ростов н/Д: Изд-во «Феникс». Изд. 2-е, 2008. – 576 с.
Островая Т.В., Черний В.И., Андронова И.А. // Междунар. неврол. журн. – 2007. – №2. – С. 2-11.
Педаченко Е.Г., Дзяк Л.А., Сирко А.Г. // Журн. Вопросы нейрохирургии им. Н.Н.Бурденко. – 2012. – №5. – С. 30-39.
Черний В.И., Островая Т.В., Андронова И.А. // Медицина неотложных состояний. – 2008. – №2(15). – С. 99-106.
Adibhatla R.M., Hatcher J.F. // Neurochem. Res. – 2005. – Vol. 30, №1. – Р. 15-23.
Adibhatla R.M., Hatcher J.F., Dempsey R.J. // J. Neurochem. – 2002. – Vol. 80. – P. 12-23.
Bullock R., Chestnut R., Chajar J. // Neurotrauma. – 2007. – Vol. 24, suppl. 1. – 106 p.
Davalos A., Castillo J., Alvarez-Sabin J. et al. // Stroke. – 2002. – Vol. 33. – Р. 2850-2857.
Faden A.I. // Arch. Neurol. – 2001. – Vol. 58. – P. 1553-1555.
Maas A.I. // Expert Opin. Investig. Drugs. – 2001. – Vol. 10. – P. 753-767.
Reilly P.L., Bullock R. (eds). Head injury, pathophysiology and management. – 2-nd ed. – 2005. – 501 p.
Rogalewski A., Schneider A., Ringelstein E.R., Schabitz W.-R. // Stroke. – 2006. – Vol. 37. – Р. 1129-1136.
Stoccetti N., Zanaboni C., Colombo A., Beretta G. // Intensive Care Medicine. – 2008. – Vol. 34 – P. 1-5.
Zweiflern R.M. // Current Med. Res. and Opinions. – 2002. – Vol. 18, suppl. 2. – P. 14-17.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).